Skip to content
DataLookout
Menu

DARENCT07538843

An Observational Study Conducted in China to Evaluate the Efficacy and Safety of Darolutamide in Combination With Androgen Deprivation Therapy (ADT) for Men With Non-metastatic Prostate Cancer That Progressed Following Prior Bicalutamide + ADT Treatment

StatusRecruiting
PhaseNot specified
SponsorBayer
Primary completion (estimated)

At risk: Primary completion moved 60 days later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 16 words
    • Primary completion pushed from Nov 1, 2029 to Dec 31, 2029
    • Secondary endpoints: details revised at 4 of 9 entries
    • Site contact updated
  2. Notable Recruitment opened
    • Start date changed from estimate of Jul 30, 2026 to Jul 31, 2026
    • Site details revised
    v4
  3. Notable Start date: Jun 1, 2026 to Jul 30, 2026v3
  4. Notable Eligibility criteria shortened, about 1 wordv2
  5. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Proportion of patients with prostatic specific antigen (PSA) undetectable within 6 months (Master Cohort)
Timeframe: up to 6 months
Proportion of patients with PSA Progression Free Survival (PSA-PFS) rate at 12 months (Sub-cohort)
Timeframe: up to 12 months

Secondary (9)

Proportion of patients with PSA50 within 3 months (Master cohort)
Proportion of patients with PSA50 within 6 months (Master cohort)
Proportion of patients with PSA90 within 3 months (Master cohort)
Proportion of patients with PSA90 within 6 months (Master cohort)
Proportion of patients with PSA undetectable within 3 months (Master cohort)
Show 4 moreShow less
Proportion of patients with PSA50/90 within 12 months (Sub-cohort)
Proportion of patients with PSA undetectable within 12 months (Sub-cohort)
Metastasis-free survival (MFS) rate at 12 months (Sub-cohort)
Proportion of patients with Treatment Emergent Adverse Events (Master and Sub-cohort)

Arms and interventions

Master-cohort (6 months follow-up)

Male patients receiving ADT+Bicalutamide for ≥ 6 months in non-metastatic hormone-sensitive prostate cancer (nmHSPC), that progressed to non-metastatic castration-resistant prostate cancer (nmCRPC)

Sub-cohort (12 months follow-up)

Male patients receiving ADT+Bicalutamide for ≥ 6 months in non-metastatic hormone-sensitive prostate cancer (nmHSPC), that progressed to non-metastatic castration-resistant prostate cancer (nmCRPC)

Drugs: Darolutamide, ADT

Sites

1 site in 1 country

  • Many locationsMultiple Locations, China